Dataset
57 of 59 inspected 503B facilities received a Form 483
When the FDA inspects a 503B compounding pharmacy, it nearly always issues an FDA Form 483. See the 57 of 59 facilities and what that rate really means.
The numbers
GLP-1 statistics joined from FDA and CMS files: inspection status across the 503B register, warning letter outcomes, and cost per pen. See the datasets.
9 statistics · Federal records only
Dataset
44 of 103 registered 503B outsourcing facilities have never been inspected
44 of the 103 FDA-registered 503B outsourcing facilities have no inspection date on record. See each 503B compounding pharmacy, with state and date.
Dataset
40 of 103 GLP-1 packages have a federal acquisition cost, priced per pen
Only 40 of 103 GLP-1 packages have a federal acquisition cost. We convert each NADAC rate per millilitre into a GLP-1 cost per pen. See the full table.
Dataset
Only 13 of 24 GLP-1 telehealth programs ship to all 50 states
Only 13 of 24 GLP-1 telehealth programs with a verified state list ship to all 50 states. Check each program and the number of states it covers.
Dataset
4 of 29 GLP-1 telehealth programs have received an FDA warning letter
Which GLP-1 telehealth programs have an FDA warning letter? 4 of the 29 we track do. See each letter, the firm behind it, and what the FDA alleged.
Dataset
76 of 157 FDA warning letters naming a GLP-1 came in the last 12 months
Our FDA warning letter database lists 157 letters that name a GLP-1 drug. 76 came in the last 12 months. See each one by date, firm and subject.
Dataset
State Medicaid programs reimbursed 11.0 million GLP-1 prescriptions in 2025
State Medicaid programs reimbursed 11.0 million GLP-1 prescriptions in 2025, from CMS State Drug Utilization Data. See each state's count per resident.
Dataset
Medicaid reimbursed at least $11.95 billion for GLP-1 drugs in 2025, before rebates. California paid $3.46 billion of it.
Medicaid GLP-1 spending hit at least $11.95 billion in 2025. California's share was 28.9%. A state-by-state ranking from CMS State Drug Utilization Data.
Dataset
Medicare Part D paid $27.0 billion for GLP-1 medications in 2024
Medicare Part D spending on GLP-1 medications reached $27.0 billion in the 2024 data year. See the total by drug and for every state, from CMS.
Questions
About these statistics
Public federal records only — the FDA registers of warning letters and outsourcing facilities, the CMS NADAC price file, the CMS Medicare Part D and State Drug Utilization files. Each page names its source and the date of the file it counted.
Because nobody else publishes the join. The sources are public, but the counts are not: no agency reports how many registered 503B facilities have never been inspected, or how many GLP-1 warning letters landed in the last twelve months. Every page here is one of those joins, with every record behind it listed.
Yes. Each page carries the figure, its denominator, its unit, its source and its as-of date in one block, plus the caveats that have to travel with it — an FDA warning letter is an allegation, not a court finding, and a blank inspection date is no inspection rather than a passed one.
Each page states the date of the data it counts, and the date the page was last updated.
The register behind the numbers
Every program, against the same record.
The enforcement letters, the pharmacies and the prices these counts are drawn from are the same ones each program is scored against on the ranking.
See the rankingRelated pages